Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Receivables (2022 - 2025)

Marker Therapeutics (MRKR) has disclosed Receivables for 4 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 116.88% to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.3 million, a 116.88% increase, with the full-year FY2024 number at $11.8 million, up 792.2% from a year prior.
  • Receivables was $2.3 million for Q3 2025 at Marker Therapeutics, up from $1.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $11.8 million in Q4 2024 to a low of $1.0 million in Q3 2024.
  • A 4-year average of $3.3 million and a median of $2.7 million in 2024 define the central range for Receivables.
  • Peak YoY movement for Receivables: skyrocketed 792.2% in 2024, then tumbled 37.31% in 2025.
  • Marker Therapeutics' Receivables stood at $3.7 million in 2022, then crashed by 63.93% to $1.3 million in 2023, then surged by 792.2% to $11.8 million in 2024, then plummeted by 80.88% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Receivables are $2.3 million (Q3 2025), $1.7 million (Q2 2025), and $2.5 million (Q1 2025).